In Brief: Johnson & Johnson's Regranex
This article was originally published in The Gray Sheet
Johnson & Johnson's Regranex: Ortho-McNeil Pharmaceutical division of J&J will begin marketing in early 1998 the first prescription biologic in the U.S. to gain an FDA nod of approval for a topical gel for use in treating diabetic foot ulcers. The genetically-engineered topical gel (becaplermin 0.01%) is indicated for treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. Active ingredients in the gel stimulate the migration of cells to the ulcer site, "encouraging the patient's body to grow new tissue," the company says in a Dec. 16 release. Becaplermin is manufactured by Emeryville, California-based Chiron Corporation...
You may also be interested in...
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.